Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS . We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS mutation who had been previously treated with other anticancer drugs. We...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2023-03, Vol.401 (10378), p.733
Hauptverfasser:	de Langen, Adrianus Johannes, Johnson, Melissa L, Mazieres, Julien, Dingemans, Anne-Marie C, Mountzios, Giannis, Pless, Miklos, Wolf, Jürgen, Schuler, Martin, Lena, Hervé, Skoulidis, Ferdinandos, Yoneshima, Yasuto, Kim, Sang-We, Linardou, Helena, Novello, Silvia, van der Wekken, Anthonie J, Chen, Yuanbin, Peters, Solange, Felip, Enriqueta, Solomon, Benjamin J, Ramalingam, Suresh S, Dooms, Christophe, Lindsay, Colin R, Ferreira, Carlos Gil, Blais, Normand, Obiozor, Cynthia C, Wang, Yang, Mehta, Bhakti, Varrieur, Tracy, Ngarmchamnanrith, Gataree, Stollenwerk, Björn, Waterhouse, David, Paz-Ares, Luis
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Adverse events Alanine Alanine transaminase Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic drugs Antitumor agents Aspartate aminotransferase Brain Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical outcomes Consent Diarrhea Disease-Free Survival Docetaxel - therapeutic use Drug withdrawal Drugs Humans Immunotherapy Inhibitors Intolerance K-Ras protein Lesions Lung cancer Lung Neoplasms - drug therapy Medical prognosis Metastases Metastasis Mutation Neutropenia Non-small cell lung carcinoma Patients PD-1 protein PD-L1 protein Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - therapeutic use Quality of life Radiation therapy Randomization Response rates Safety Small cell lung carcinoma Statistical analysis Survival Toxicity Transaminases Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!